Published in JAMA on December 26, 2012
Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer (2016) 2.91
Impact of hepatitis C virus eradication on hepatocellular carcinogenesis. Cancer (2015) 2.67
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med (2013) 2.63
A Canadian screening program for hepatitis C: is now the time? CMAJ (2013) 2.33
Global control of hepatitis C: where challenge meets opportunity. Nat Med (2013) 2.22
Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis. Aliment Pharmacol Ther (2014) 2.18
Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med (2015) 2.07
Hepatitis C. Lancet (2015) 1.95
The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med (2015) 1.89
Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C. Gut (2013) 1.88
An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol (2015) 1.86
A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. Gut (2014) 1.84
Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population. JAMA Intern Med (2016) 1.77
Pathobiology of liver fibrosis: a translational success story. Gut (2015) 1.72
HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology (2014) 1.46
Novel therapies for hepatitis C - one pill fits all? Nat Rev Drug Discov (2013) 1.43
Clinical impact of treatment timing for chronic hepatitis C infection: a decision model. J Viral Hepat (2015) 1.40
The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. J Viral Hepat (2013) 1.37
The changing burden of hepatitis C virus infection in the United States: model-based predictions. Ann Intern Med (2014) 1.33
Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. Gastroenterology (2015) 1.28
The hepatitis C cascade of care: identifying priorities to improve clinical outcomes. PLoS One (2014) 1.25
Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response. Clin Infect Dis (2015) 1.22
Current and future disease progression of the chronic HCV population in the United States. PLoS One (2013) 1.17
Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C? Antiviral Res (2014) 1.17
HCV and HIV co-infection: mechanisms and management. Nat Rev Gastroenterol Hepatol (2014) 1.16
Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C. J Viral Hepat (2014) 1.16
Cost-effectiveness of screening for hepatitis C in Canada. CMAJ (2015) 1.16
Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nat Commun (2015) 1.14
Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition. Cancer Cell (2016) 1.14
Hepatitis C, stigma and cure. World J Gastroenterol (2013) 1.13
Emerging therapies for the treatment of hepatitis C. EMBO Mol Med (2014) 1.09
Sustained virological response to treatment in patients with chronic hepatitis C. JAMA (2013) 1.08
Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response. Hepatology (2014) 1.05
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens. Clin Pharmacol Ther (2013) 1.03
Diagnosis and treatment of hepatocellular carcinoma: An update. World J Hepatol (2015) 1.02
Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States. Value Health (2013) 1.01
Impact of new therapeutics for hepatitis C virus infection in incarcerated populations. Top Antivir Med (2013) 1.00
Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World J Gastroenterol (2014) 0.98
Chronic hepatitis C: This and the new era of treatment. World J Hepatol (2016) 0.98
Interferon-free combination therapies for the treatment of hepatitis C: current insights. Hepat Med (2015) 0.97
Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. J Hepatol (2014) 0.96
Hepatocellular Carcinoma in Patients with a Sustained Response to Anti-Hepatitis C Therapy. Int J Mol Sci (2015) 0.95
Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation. J Hepatol (2016) 0.95
Hepatitis C Disease Burden in the United States in the era of oral direct-acting antivirals. Hepatology (2016) 0.95
Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits. BMC Infect Dis (2015) 0.94
Oxidative stress and hepatic Nox proteins in chronic hepatitis C and hepatocellular carcinoma. Free Radic Biol Med (2014) 0.94
Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study. BMC Infect Dis (2013) 0.93
Role of lymphocytes in liver cancer. Oncoimmunology (2013) 0.93
Hepatitis C virus screening practices and seropositivity among US veterans born during 1945 - 1965. BMC Res Notes (2014) 0.93
Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs. Addiction (2015) 0.92
Hepatitis C virus therapy is associated with lower health care costs not only in noncirrhotic patients but also in patients with end-stage liver disease. Aliment Pharmacol Ther (2013) 0.92
Hepatitis C virus-induced hepatocellular carcinoma. Clin Mol Hepatol (2015) 0.91
Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis. J Gastroenterol (2016) 0.90
Serum Alpha-Fetoprotein Has High Specificity for the Early Detection of Hepatocellular Carcinoma After Hepatitis C Virus Eradication in Patients. Medicine (Baltimore) (2015) 0.90
Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa. Int J Nanomedicine (2014) 0.89
Treatment of chronic HCV with sofosbuvir and simeprevir in patients with cirrhosis and contraindications to interferon and/or ribavirin. Am J Gastroenterol (2015) 0.89
Significance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinoma. World J Gastroenterol (2016) 0.88
Clinical outcomes of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. Hepatology (2014) 0.87
Hepatitis C cirrhosis: New perspectives for diagnosis and treatment. World J Hepatol (2015) 0.87
Increasing prevalence of cirrhosis among U.S. adults aware or unaware of their chronic hepatitis C virus infection. J Hepatol (2016) 0.87
All-cause mortality and liver-related outcomes following successful antiviral treatment for chronic hepatitis C. Dig Dis Sci (2014) 0.86
Origin of hepatitis C virus genotype 3 in Africa as estimated through an evolutionary analysis of the full-length genomes of nine subtypes, including the newly sequenced 3d and 3e. J Gen Virol (2014) 0.86
Acceptability and yield of birth-cohort screening for hepatitis C virus in a Canadian population being screened for colorectal cancer: a cross-sectional study. CMAJ Open (2015) 0.85
Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study. CMAJ Open (2016) 0.85
Valuing cure: bridging cost-effectiveness and coverage decisions for hepatitis C therapy. Hepatology (2014) 0.85
SASLT guidelines: Update in treatment of Hepatitis C virus infection. Saudi J Gastroenterol (2016) 0.85
Management of hepatitis C infection before and after liver transplantation. World J Gastroenterol (2015) 0.85
Hepatitis C genotype influences post-liver transplant outcomes. Transplantation (2015) 0.85
A public health approach to hepatitis C control in low- and middle-income countries. PLoS Med (2015) 0.85
Hepatitis C NS5A protein: two drug targets within the same protein with different mechanisms of resistance. Curr Opin Virol (2014) 0.84
Long-term Outcomes After Liver Transplantation Among Human Immunodeficiency Virus-Infected Recipients. Transplantation (2016) 0.84
Dimension of chronic hepatitis C virus in HIV-infected patients in the interferon-free era: an overview from south Spain. Eur J Clin Microbiol Infect Dis (2015) 0.84
Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis. PLoS One (2014) 0.84
Molecular classification of hepatocellular carcinoma: potential therapeutic implications. Hepat Oncol (2015) 0.84
Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES. Hepatology (2016) 0.84
Treatment of genotype 1 HCV infection in the HIV coinfected patient in 2014. Curr HIV/AIDS Rep (2013) 0.83
Prevalence and epidemiological correlates and treatment outcome of HCV infection in an Italian prison setting. BMC Public Health (2013) 0.83
Hepatitis C and kidney disease: An overview and approach to management. World J Hepatol (2015) 0.83
Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis. Hepatology (2016) 0.82
Transmitted/founder hepatitis C viruses induce cell-type- and genotype-specific differences in innate signaling within the liver. MBio (2015) 0.82
Extrahepatic manifestations of hepatitis C infection: navigating CHASM. Curr HIV/AIDS Rep (2015) 0.82
Promotion of Cancer Stem-Like Cell Properties in Hepatitis C Virus-Infected Hepatocytes. J Virol (2015) 0.81
Persistence of hepatitis C virus during and after otherwise clinically successful treatment of chronic hepatitis C with standard pegylated interferon α-2b and ribavirin therapy. PLoS One (2013) 0.81
Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin. Dig Dis Sci (2014) 0.81
Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality. BMC Gastroenterol (2014) 0.81
New treatments for hepatitis C virus (HCV): scope for preventing liver disease and HCV transmission in England. J Viral Hepat (2016) 0.81
Impact of treatment against hepatitis C virus on overall survival of naive patients with advanced liver disease. Antimicrob Agents Chemother (2014) 0.80
The hepatitis C genotype 1 paradox: cost per treatment is increasing, but cost per cure is decreasing. Can J Gastroenterol Hepatol (2015) 0.80
Treatment strategies for chronic hepatitis C prior to and following liver transplantation. World J Hepatol (2016) 0.80
Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients. Value Health (2016) 0.80
Strategies for treating chronic HCV infection in patients with cirrhosis: latest evidence and clinical outcomes. Ther Adv Chronic Dis (2015) 0.80
NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations. Int J Mol Sci (2016) 0.80
Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol (2016) 0.80
Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review. Ann Intern Med (2017) 0.79
Economic burden of hepatitis C in Egypt: the future impact of highly effective therapies. Aliment Pharmacol Ther (2015) 0.79
Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance. Clin Gastroenterol Hepatol (2016) 0.79
Frontiers in the treatment of hepatitis C virus infection. Gastroenterol Hepatol (N Y) (2014) 0.79
The effect of hepatitis C virologic clearance on cardiovascular disease biomarkers in human immunodeficiency virus/hepatitis C virus coinfection. Open Forum Infect Dis (2014) 0.79
APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. Hepatol Int (2016) 0.79
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med (2004) 16.21
Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med (2011) 12.09
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med (2009) 10.21
Treatment of HCV infection by targeting microRNA. N Engl J Med (2013) 9.91
The Collaborative Cross, a community resource for the genetic analysis of complex traits. Nat Genet (2004) 9.37
Telaprevir for previously treated chronic HCV infection. N Engl J Med (2010) 8.33
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med (2014) 8.13
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology (2010) 7.86
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med (2008) 7.22
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet (2012) 6.93
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med (2014) 6.31
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology (2007) 6.12
Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med (2007) 6.11
Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology (2013) 5.88
Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med (2007) 5.83
Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology (2007) 5.53
Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology (2003) 5.40
Primary biliary cirrhosis. Hepatology (2009) 5.35
Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology (2008) 5.07
Real-time elastography for noninvasive assessment of liver fibrosis in chronic viral hepatitis. AJR Am J Roentgenol (2007) 4.70
SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology (2007) 4.44
Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology (2003) 4.33
A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology (2008) 4.23
Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med (2003) 4.12
The nature and identification of quantitative trait loci: a community's view. Nat Rev Genet (2003) 3.96
Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology (2009) 3.89
Histological outcome during long-term lamivudine therapy. Gastroenterology (2003) 3.88
2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology (2008) 3.82
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology (2006) 3.80
Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med (2007) 3.72
Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology (2011) 3.70
Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med (2009) 3.70
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med (2005) 3.46
The Rotterdam Study: 2010 objectives and design update. Eur J Epidemiol (2009) 3.44
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med (2014) 3.40
Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology (2009) 3.35
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet (2005) 3.33
Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol (2009) 3.28
The Rotterdam Study: 2012 objectives and design update. Eur J Epidemiol (2011) 3.26
Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology (2011) 3.24
Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology (2004) 3.19
Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology (2006) 3.18
Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nat Genet (2011) 3.18
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med (2015) 3.16
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet (2010) 3.15
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med (2015) 3.13
Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology (2005) 3.10
Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology (2003) 3.09
Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology (2010) 3.02
Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology (2011) 2.99
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology (2004) 2.98
Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology (2004) 2.97
Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB J (2002) 2.96
Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol (2012) 2.93
Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am J Gastroenterol (2013) 2.89
Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology (2010) 2.82
Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology (2008) 2.80
Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography. Radiology (2009) 2.79
Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology (2006) 2.78
Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res (2005) 2.78
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int (2011) 2.77
A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease. Nat Genet (2007) 2.75
Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med (2011) 2.72
Interleukin 6/gp130-dependent pathways are protective during chronic liver diseases. Hepatology (2003) 2.68
Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology (2003) 2.66
Patients with acute on chronic liver failure display "sepsis-like" immune paralysis. J Hepatol (2005) 2.66
Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology (2011) 2.64
Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology (2002) 2.64
Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology (2003) 2.64
Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology (2006) 2.62
Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med (2010) 2.61
Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol (2010) 2.58
Humanized mice for modeling human infectious disease: challenges, progress, and outlook. Cell Host Microbe (2009) 2.58